

RESEARCH COMMUNICATION

Epidemiologic Analysis of the Tehran Cancer Institute Data System Registry (TCIDSR)

B Larijani^{1*}, M Shirzad², MA Mohagheghi³, V Haghpanah², AR Mosavi-Jarrahi^{3,4}, SM Tavangar⁵, AR Vassigh², A Hossein-Nezhad², F Bandarian², R Baradar-Jalili²

Abstract

Objective: To review epidemiological data on thyroid cancer in Iran.

Methods: The Tehran Cancer Institute Data System Registry (TCIDSR) was used to identify patients with different histological types of thyroid cancer (TC) in Iran. Data were analysed from 438 thyroid cancer cases identified by the TCIDSR in 1998-99. Disease prevalence was calculated with reference to age, time and place.

Results: The TCIDSR recorded 438 primary malignancies of the thyroid gland: papillary, follicular, medullary, and anaplastic carcinomas accounted for 67.1%, 10.7%, 5.3% and 4.3% of cases, respectively. The remaining 12.6% were classified as OD (other diagnoses). The prevalence of TC was highest in ethnic Farsis. The age range of patients was 8-85 years. Mean patient age was 44.52 ± 17.03 years (mean $\pm$ SD) overall, 47.74 ± 18.10 years in female patients and 43.04 ± 16.34 years in male patients. Anaplastic (6.5% vs. 3.3%) and medullary (10.0% vs. 3.0%) cancers were more common in men than women.

Conclusion: This study was undertaken to define the epidemiological aspects of thyroid carcinoma in Iran, an area of endemic iodine deficiency until fairly recently. Against expectation for an iodine-deficient area, the frequency distribution of tumours in our study was closer to that seen in iodine-rich areas. Additional research on the risk factors for thyroid cancer – genetic, ethnic, geographic and environmental – is needed to explain the high incidence of PTC overall, and among ethnic Farsis in particular, in Iran.

Asian Pacific J Cancer Prev, 5, 36-39

Introduction

Thyroid cancer (TC) is the most common endocrine malignancy, with worldwide incidence rates that are generally lower than 3 per 100,000 for men and 5 per 100,000 for women (Franceschi et al., 1994; Negri et al., 1999; Parkin et al., 1999; Whelan, IARC Sci Publ 102). TC has four main histological types: papillary (PTC), follicular (FTC), medullary (MTC), and anaplastic (ATC). The PTC is the most prevalent type, and is three times more common in women than men (Negri et al., 1999; Parkin et al., 1999; Whelan, IARC Sci Publ 102; Mulla and Margo, 2000). There is also marked geographic, ethnic, and temporal variation in incidence rates and genetic and environmental influences play major roles in TC pathogenesis (Parkin et al., 1999; Whelan, IARC Sci Publ 102). Longitudinal data from

population-based registries show that the incidence of PTC has increased up to five-fold in a number of countries over the past 60 years (Whelan, IARC Sci Publ 102; Mulla and Margo, 2000; Christensen et al., 1984; Ain, 1995). TC shows considerable ethnic and geographic variation, and the highest incidence rates are reported in areas of high iodine intake (Ferich et al., 1997). The overall prognosis for TC is worse, however, in endemic goitre regions, in comparison with regions with an adequate dietary iodine intake, perhaps because of the higher incidence of undifferentiated TC in iodine-deficient areas (Galanti et al., 1997; Salabe, 1994). There is as yet no consensus on this matter, however (Bacher et al., 1997). Goitre used to be endemic in Iran until the introduction of universal iodine supplementation ten years ago (Kimiagar et al., 1990; Azizi et al., 1990). There are difficulties, therefore, in assessing trends in the epidemiology

¹Director and Chief Scientific Officer, Endocrinology & Metabolism Research Centre, Tehran University of Medical Sciences, ²Researcher, Endocrinology & Metabolism Research Centre, Tehran University of Medical Sciences, ³The Cancer Institute, Imam Khomeini University Hospital, Tehran, ⁴Dept. of Social Medicine, Medical School, Shahid Beheshti University of Medical Sciences, ⁵Department of Pathology, Doctor Shariati University Hospital, Tehran

*Corresponding Author: Endocrinology & Metabolism Research Centre, Fifth Floor, Doctor Shariati Hospital, North Kargar Avenue, Tehran 14114, Iran. Phone: (+09821) 802 6902 – 03 Fax: (+09821) 802 93 99 E-mail: emrc@sina.tums.ac.ir

of TC. We studied the epidemiology of TC at the Tehran Cancer Institute Data System Registry (TCIDSR) in 1998-99, based on 438 cases.

Materials and Methods

Information for the present study was obtained from the Tehran Cancer Institute Registry, which contains data on malignancies diagnosed in Tehran hospitals and referrals from all over Iran. All pathologists in Tehran are required by law to notify the relevant registries of any case of cancer they report on, with local registries reporting to the TCIDSR, which then records the data using 'Can.Reg' software. The 438 cases were assigned to one of five histological categories: PTC, FTC, MTC, ATC, and OD (Other Diagnoses), the latter group containing cases of TC with metastatic involvement of the thyroid, lymphoma, or benign neoplasia.

Information collected by the registry includes general patient information (age, gender, and district of residence), tumour site and histology, as defined by the 2nd edition of the International Classification of Diseases for Oncology (ICD-O) (WHO, 1996), and time of diagnosis. Qualitative variables were analysed with the Chi-squared test. All statistical analyses were carried out using SPSSv10 software.

Results

We reviewed the records of 438 cases of thyroid cancer, within the framework of the Tehran Hospitals' Cancer Registration Plan. All cases referred from the provinces in 1998-99 were grouped according to sex, age, ethnicity, and histopathology. 139 (31.7%) of the patients were men, and 299 women (68.3%). Patient age ranged from 8 to 85 years. Mean patient age was 44.52 ± 17.03 years. Male patients were significantly older than female patients (47.74 ± 18.10 vs. 43.04 ± 16.34 years; $p < 0.008$).

Figure 1 shows the number of cases in each age group,




Figure 1. Age Distribution of Thyroid Cancer Cases in Iran

and indicates that thyroid cancer is most prevalent in the 30-and-over age group.

Table 1 shows the prevalence of cases by province of origin. 69.3% of cases were reported as originating from the province of Tehran. The ethnic origin of 75.2% of cases was Farsi, with, at the other end of the spectrum, only 0.3% of cases being of Baluchi ethnic origin. After patients of Farsi origin, Turk patients accounted for 17.8% of cases, and Kurdish patients for 3.1% of cases.

PTC accounted for 67.1% of cases, FTC for 10.7%, MTC for 5.3%, ATC for 4.3%, and OD classification for 12.6% of cases. The following histopathologic subtypes were also recorded in patients' files:

In papillary carcinomas: 9.8% of cases were of follicular variant; In medullary carcinomas: amyloid stroma was present in 0.7%;

In anaplastic carcinomas: carcinoma undifferentiated NOS, giant cell and spindle cell variants were found in 2.5%, 0.5% and 0.2% respectively.

Table 2 shows the prevalence by gender of different morphological subtypes.

Discussion

This is an epidemiological survey of cases of thyroid cancer recorded by the Cancer Institute at Imam Khomeini Hospital in Tehran, using a data system registry. This project is part of a general survey of endocrine cancers being carried out in collaboration with the Endocrinology & Metabolism Research Centre (EMRC) of Tehran University of Medical Sciences. Given the importance of registry systems and Surveillance Epidemiology and End Results (SEER) datasets

Table 1. Distribution of Thyroid Cancer Cases by Province

Province	Frequency	Percentage
E. Azerbaijan	4	1.5
W. Azerbaijan	6	2.3
Ardebil	2	0.8
Esfahan	5	1.9
Tehran	183	69.3
Khorassan	1	0.4
Zanjan	3	1.1
Semnan	1	0.4
Qazvin	7	2.7
Qom	6	2.3
Kordestan	5	1.9
Kermanshah	3	1.1
Golestan	1	0.4
Guilan	5	1.9
Lorestan	5	1.9
Mazandaran	13	4.9
Markazi	6	2.3
Hamadan	8	3.0
TOTAL	264	100.0

Only provinces with registered cases have been included

in epidemiological surveys, clinical trials and, ultimately, healthcare planning, it is vital to incorporate this approach into the general mindset of healthcare systems. As data registration systems are still in their infancy in Iran, errors are only natural along the way. The number of missing records in this study is significant, and the records that are present in the registry are in many ways flawed, sometimes through unforeseen circumstances rather than indifference. We must follow the example of countries more experienced than ourselves in this domain, the Scandinavians in particular: Sweden boasts registration coverage of 97 percent. For example, initial data entry in our study did not include either tumour stage and grade or the risk factor profile of patients. The original datasheets, however, contained all this information, correctly and accurately recorded. The data entry process therefore needs to be reformed. There are also many instances of the tumour ICD-O code being incorrectly recorded. One of the positive steps taken by the Cancer Institute has been to design the IARC-approved CAN.REG software. Unlike previous versions, the latest version of CAN.REG can operate in a Windows environment, greatly facilitating data entry.

A quality control (QC) step must be incorporated into the registration process in order to monitor the accuracy and data collection and entry. The QC plan is currently in its preliminary phase. Ultimately, it is by driving home the importance of data registration that public and private medical institutions will be compelled to act collectively and cohesively in this regard.

The female-to-male ratio in this study was 2.1:1, consistent with the female predominance reported elsewhere (Bacher et al., 1997; Al Nua'im et al., 1996; Kuijpers et al., 1994; Santos and Swerdlow, 1993). A higher proportion of men than women were affected by ATC, again agreeing with previous studies (Bacher et al., 1997; Ain, 1998). This may partly explain why thyroid cancer has a worse outcome in men. Patients with ATC were older than patients in the other

groups. Similar results have been reported in other series (Bacher et al., 1997; Al Nua'im et al., 1996; Ain, 1998; Pomorski et al., 1996).

The relationship between iodine nutrition and thyroid carcinoma pathogenesis is complex (Salabe, 1994; Lind et al., 1998; Franceschi, 1998). Epidemiological data show higher rates in populations with higher iodine intake (Parkin et al., 1999; Whelan, IARC Sci Publ 102; Connolly et al., 1970). Improved iodine intake in previously iodine-deficient communities has also been associated with an increased incidence of PTC (Bacher et al., 1997; Peterson et al., 1996). This so-called papillarization is characterized by an increase in the ratio of papillary to follicular cancers, a decrease in PTC size, and an attenuation of the malignant phenotype (Peterson et al., 1996; Rolon, 1986). There is, however, no clear relationship between increased dietary iodine and higher total TC rates (Peterson et al., 1996; Rolon, 1986). Iodine intake is associated with an increase in the incidence papillary and corresponding decrease in that of follicular TC (Ferich et al., 1997; Coard, 1997). Earlier reviews have reported an increased incidence of FTC in iodine-deficient areas, accounting for as much as 30-40% of all cases of TC in these areas (Ferich et al., 1997; Kimiagar et al., 1990; Pomorski et al., 1996). More recent studies support this trend (Pomorski et al., 1996; Coard, 1997), which may be more obvious in men (Peterson et al., 1996). Interestingly, following the introduction of iodine supplementation in iodine-deficient areas, the proportion of PTC has increased at the expense of ATC (Bacher et al., 1997; Peterson et al., 1996; Agrawal et al., 1996). This is confirmed by our findings, in which two-thirds of our cases were PTC. When we consider that Iran was an iodine-deficient country during the years in which the subjects of this study had sought medical care, this observation argues against a possible cause-and-effect relationship between iodine deficiency and follicular carcinoma (Kimiagar et al., 1990; Azizi et al., 1990). The lower incidence of FTC may also explain the

Table 2. Thyroid Cancer in Iran by ICDOM Group and Gender

Gender	ICDOM	OD	Anaplastic				Follicular NOS	Papillary		Medullary		TOTAL
			Undiff. NOS	NOS	Giant Cell	Spindle Cell		NOS	Follicular variant	NOS	Amyloid stroma	
MALE	Count	14	4	3	2	0	11	75	16	12	2	139
	Gender (%)	10.1	2.9	2.2	1.4		7.9	54.0	11.5	8.6	1.4	100
	ICDOM(%)	25.5	36.4	60.0	100		23.4	29.9	37.2	60.0	66.7	31.7
	Total(%)	3.2	0.9	0.7	0.5		2.5	17.1	3.7	2.7	0.5	31.7
FEMALE	Count	41	7	2	0	1	36	176	27	8	1	299
	Gender(%)	13.7	2.3	0.7		0.3	12.0	58.9	9.0	2.7	0.3	100
	ICDOM(%)	74.5	63.6	40.0		100	76.6	70.1	62.8	40.0	33.3	68.3
	Total(%)	9.4	1.6	0.5		0.2	8.2	40.2	6.2	1.8	0.2	68.3
TOTAL	Count	55	11	5	2	1	47	251	43	20	3	438
	Gender(%)	12.6	2.5	1.1	0.5	0.2	10.7	57.3	9.8	4.6	0.7	100
	ICDOM(%)	100	100	100	100	100	100	100	100	100	100	100
	Total(%)	12.6	2.5	1.1	0.5	0.2	10.7	57.3	9.8	4.6	0.7	100

Undiff. = undifferentiated; NOS = not otherwise specified; ICDOM = International Classification of Disease for Oncology-Morphology; OD = other diagnoses;

low incidence of ATC in our study (Agrawal et al., 1996).

Regarding the information itself, there are three points to make:

1. The homogeneity of the samples means that the findings of the study can be extrapolated to the general population.

2. Ten years ago, the government instituted a nationwide iodine supplementation programme, and its effect on the distribution of thyroid cancer in Iran must be studied, given the clear association between iodine status and thyroid cancer (Kimiagar et al., 1990; Azizi et al., 1990; From et al., 2000; Mellemegaard et al., 1998).

3. Any study of the distribution of thyroid cancer must naturally be in the context of the genetic and ethnic diversity of the population of Iran.

Acknowledgements

We would like to express our gratitude to the people who helped us in the completion of this project: MR Amini, MD; N Poorpezhshk, MD; S Aghakhani, MD; GR Habibi, MD; H Haerizadeh, MD; and Z Basaeri, as well as the staff of Tehran Cancer Institute.

References

- Agrawal SH, Parikh DM, Parikh HK, et al (1996). Histologic trends in thyroid cancer 1969-1993: a clinico-pathologic analysis of the relative proportion of anaplastic carcinoma of the thyroid. *J Sur Onco*, **63**, 251-5.
- Ain KB (1995). Papillary Thyroid carcinoma. *Endocrinol Metab Clin North Am*, **24**, 711-60.
- Ain KB (1998). Anaplastic thyroid carcinoma: behavior, biology, and therapeutic approaches. *Thyroid*, **8**, 715-26.
- Al Nuaim AR, Ahmed M, Bakheet B, et al (1996). Papillary thyroid cancer in Saudi Arabia: clinical, pathologic and management characteristics. *Clin Nucl Med*, **21**, 307-11.
- Azizi F, Kimiagar M, Nafarabadi M, et al (1990). Current state of iodine deficiency in the Islamic Republic of Iran. *EMR Health Survey*, **8**, 23-7.
- Bacher CS, Ricabona C, Totsch M, et al (1997). Incidence and characteristic of thyroid carcinoma after iodine prophylaxis in an endemic goiter country. *Thyroid*, **7**, 733-41.
- Christensen SB, Ljungberg O, Tibblin S (1984). Thyroid carcinoma in Maloma, 1960-1977. *Cancer*, **53**, 1625-33.
- Coard KC (1997). The pathology of thyroid neoplasm at the University Hospital of the West Indies. *W I Med J*, **46**, 80-2.
- Connolly RJ, Vidor GI, Stewart JC (1970). Increase in thyrotoxicosis in endemic goiter area after iodination of bread. *Lancet*, **1**, 500.
- Ferich L, Akslen LA, Glatte E (1997). Increased risk of thyroid cancer among Norwegian women married to fishery workers: A retrospective cohort study. *BJC*, **76**, 385-9.
- Franceschi S, La Vecchia C (1994). Cancer of the thyroid. In: Doll RI, Fraumeni JF Jr., Muir CS (Eds.). Trends in Cancer Incidence and Mortality; Cold Spring Harbor. Cold Spring Harbor Press, **19/20**, 393-424.
- Franceschi S (1998). Iodine intake and thyroid carcinoma: A potential risk factor. *Exp Clin Endocrinol Diabetes*, **106** (suppl.3), 38-44.
- From G, Mellemegaard A, Knudsen N, Jorgensen T, Perrild H (2000). Review of thyroid cancer cases among patients with previous benign thyroid disorders. *Thyroid*, **10**, 697-700.
- Galanti MR, Ekbom A, Grimelius L, et al (1997). Parental cancer and risk of papillary and follicular thyroid carcinoma. *Br J Cancer*, **75**, 451-6.
- Kimiagar M, Azizi F, Navai L, et al (1990). Survey of iodine deficiency in a rural area near Tehran: association of food intake and endemic goiter. *Eur J Clin Nutr*, **44**, 17-22.
- Kuijpers JL, Coebergh JW, Van Heijden LH, et al (1994). Thyroid cancer in southeastern Netherlands, 1970-1989: Trends in incidence, treatment and survival. *Ned Tijdscher Geneesk*, **138**, 464-8.
- Lind P, Langsteger W, Molnar M, et al (1998). Epidemiology of thyroid disease in iodine sufficiency. *Thyroid*, **8**, 1179-83.
- Mellemegaard A, From G, Jorgensen T, et al (1998). Cancer risk in individuals with benign thyroid disorders. *Thyroid*, **8**, 751-4.
- Mulla ZD, Margo CE (2000). Primary malignancies of the thyroid: Epidemiological analysis of the Florida cancer data system registry. *Ann Epidemiol*, **10**, 24-30.
- Negri E, Ron E, Franceschi S, et al (1999). A pooled analysis of case-control studies of thyroid cancer. *Cancer Cause Control*, **10**, 131-42.
- Parkin DM, Muir CS, Whelan SL, et al (1999). Cancer incidence in five continents. IARC Sci Publ 5, Lyon.
- Peterson B, Colean MP, Ron E, et al (1996). Iodine supplementation in Sweden and regional trends in thyroid cancer incidence by histopathologic type. *Int J Cancer*, **65**, 13-9.
- Pomorski L, Cywinski J, Rybinski K (1996). Cancer in hyperthyroidism. *Neoplasma*, **43**, 217-9.
- Rolon PA (1986). [Cancer of the thyroid in an area of endemic goiter. "Pappillarization" with prophylactic iodization]. *Ann Pathol*, **6**, 170-5.
- Salabe GB (1994). Aetiology of thyroid cancer and epidemiological overview. *Thyroid*, **6**, 11-19.
- Santos SI, Swerdlow AJ (1993). Sex differences in the risk of hormone-dependent cancers. *Am J Epidemiol*, **138**, 10-28.
- Whelan SL, Parkin DM, Masuyer E (Eds.). Patterns of cancer in five continents. IARC Sci Publ 102, Lyon.
- World Health Organization International Classification of Disease for Oncology. WHO, Geneva, 1996.